Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma
Sponsor: CURE Childhood Cancer, Inc.
This PHASE1 trial investigates Neuroblastoma and is currently completed. CURE Childhood Cancer, Inc. leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Dec 2018 — Feb 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Mar 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CURE Childhood Cancer, Inc.
- St. Jude Children's Research Hospital
For direct contact, visit the study record on ClinicalTrials.gov .